NovoCure

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division.

CEO

Ashley Cordova

CEOAshley Cordova

Employees

1,488

Employees1,488

Headquarters

St. Helier, Jersey

HeadquartersSt. Helier, Jersey

Founded

2000

Founded2000

Employees

1,488

Employees1,488

NVCR Key Statistics

Market cap

2.07B

Market cap2.07B

Price-Earnings ratio

-11.88

Price-Earnings ratio-11.88

Dividend yield

—

Dividend yield—

Average volume

888.56K

Average volume888.56K

High today

$19.29

High today$19.29

Low today

$17.40

Low today$17.40

Open price

$18.94

Open price$18.94

Volume

1.43M

Volume1.43M

52 Week high

$34.13

52 Week high$34.13

52 Week low

$11.88

52 Week low$11.88

NVCR News

Benzinga 12h

NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025

NovoCure Ltd NVCR reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents. Sales...

TipRanks 12h

NovoCure’s Strong Market Penetration and Promising Growth Prospects Justify Buy Rating

NovoCure (NVCR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright mainta...

TipRanks 3d

NovoCure’s Optune Lua Gains CE Mark Approval

The latest update is out from NovoCure ( (NVCR) ). On April 22, 2025, Novocure announced that its Optune Lua® device received CE Mark approval for treating adu...

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

28.6%

Sell